Retinopathy of Prematurity
Focused reporting on ROP screening, diagnosis, and management. Includes updates on guidelines, technology, and neonatal care collaboration.
Three-year FIREFLEYE outcomes reported for aflibercept vs laser in ROP
Children treated with intravitreal aflibercept 0.4 mg for retinopathy of prematurity (ROP) maintained stable disease control and age-appropriate visual function through 3...
Study highlights link between obesity indicators and risk of retinopathy
Multiple obesity indicators are significantly associated with an increased risk of retinopathy, with the weight-adjusted waist index (WWI) showing the strongest predictive...
Declining trends in retinopathy of prematurity screening eligibility among U.S. infants
A recent national study analyzed trends in retinopathy of prematurity (ROP) screening eligibility among U.S. infants from 2003 to 2022, revealing a...
Top risk factors for ROP reactivation after IVI anti-VEGF injection
All anti-vascular endothelial growth factor (anti-VEGF) agents carry a risk of retinopathy of prematurity (ROP) reactivation, with a higher risk with ranibizumab 0.25 mg than with bevacizumab 0.625 mg, according...
Results of intravitreal aflibercept for treatment of acute-phase ROP in premature neonates
Twenty-four-week data from the FIREFLEYE randomized phase 3 study suggest intravitreal aflibercept for treatment of acute-phase retinopathy of prematurity (ROP) in premature neonates is not associated with clinically relevant effects...
Aflibercept and laser therapy show comparable success rates in ROP
Treatment with intravitreal aflibercept 0.4 mg (IVT-AFL) demonstrates sustained absence of retinopathy of prematurity (ROP) through the first 2 years of a child’s life, while maintaining appropriate visual function, according...
Ranibizumab shows higher recurrence risk in ROP treatment
Based on a comparative study, ranibizumab (IVR) is associated with a higher risk of recurrence and retreatment for retinopathy of prematurity (ROP) compared to bevacizumab (IVB). Additionally, the study, which...
Study compares efficacy of ranibizumab and aflibercept in diabetic retinopathy treatment
Both ranibizumab (LU) and aflibercept (AF) injections into the vitreous cavity effectively reduce the expression of vascular-related factors in patients with diabetic retinopathy (DR), however, AF demonstrates a more significant...
Meta-analysis offers insights into ROP treatments
In patients with retinopathy of prematurity (ROP), anti-VEGF therapy is associated with a higher retreatment rate but a lower incidence of myopia compared to laser therapy, according to a study....
Premature infants receiving ROP treatment show personal-social development delay
Premature infants treated for Type 1 retinopathy of prematurity (ROP) and aggressive ROP (A-ROP) with intravitreal bevacizumab (IVB) and intravitreal aflibercept (IVA) may experience delay in personal and social development...
Link found between parenteral nutrition duration and ROP, updated prediction models promote improved screening
The duration of parenteral nutrition in premature infants (PND) has a significant impact on the development and severity of retinopathy of prematurity (ROP), according to a study. Infants who receive...